Exercise program during intensive cancer treatment in children and teenagers
Tests a supervised exercise program in children and teenagers having cancer treatment.
Plain-language title generated from the registry record
Registry title: Evaluation of an Exercise Intervention During Intensive Medical Treatment in Pediatric Oncology.
Key facts
- Where
- Berlin, Bonn, Cologne, Essen, Frankfurt, Hamburg, Jena, Mainz, München, Nuremberg, Stuttgart, and Ulm, GermanySee the 13 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and teenagers aged 3 to 18 years who have just been diagnosed with cancer and are starting treatment. It tests a 6-month exercise program.
- Age
- 3 to 18 years
- Sex
- All sexes
- Disease stage
- Cancer diagnosed no more than 6 weeks ago (first diagnosis, second cancer or relapse), with treatment meant to remove all of the disease.
- Earlier treatment
- Must be in active cancer treatment at a pediatric oncology center. Watch-and-wait or surgery alone without ongoing treatment does not count.
Main reasons for not taking part
- Not in active cancer treatment
- Medical limits that do not allow the study plan to be followed
- Life expectancy under 6 months
- Not insured by a German statutory health insurer
- Cannot communicate in German or English, and no interpreter or multilingual staff at the site
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 3 and 18 years old?
Source: NCT07647471, who can take part
Where in Germany
- Charité-Universitätsmedizin Berlin, Department of Pediatric Oncology/HematologyBerlin, GermanyContact: Pablo Hernaiz DrieverTaking people
- University of Bonn Medical Center, Department of Pediatric Hematology/Oncology,Bonn, GermanyContact: Gabriele CalaminusTaking people
- Children's Hospital Amsterdamer Straße, ; Clinic for Children and Youth Medicine; Department for pediatric hematology/oncologyCologne, GermanyContact: Meinolf SiepermannTaking people
- University Hospital Cologne, Department of Pediatric Oncology and Hematology, Children's HospitalCologne, GermanyContact: Thorsten SimonTaking people
- University Hospital Essen, Department of Pediatric Hematology/Oncology, Center for Child and Adolescent Medicine, Clinic for Pediatrics IIIEssen, GermanyContact: Uta DirksenTaking people
- Universitätsmedizin Frankfurt, Department of Pediatrics, Pediatric Oncology and HaematologyFrankfurt, GermanyContact: Mirjam DieckelmannTaking people
- Universitätsklinikum Hamburg-Eppendorf, Department of Pediatric Hematology and Oncology, Hubertus Wald Tumor Center, University Cancer Center HamburgHamburg, GermanyContact: Gabriele EscherichTaking people
- Universitätsklinikum Jena, Klinik für Kinder- und JugendmedizinJena, GermanyContact: Jana ErnstTaking people
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Department of Pediatric Hematology/OncologyMainz, GermanyContact: Jörg FaberTaking people
- Pädiatrische Hämatologie und Onkologie, Zelltherapie Zentrum für Kinder- und Jugendmedizin Eine Kooperation der München Klinik und des TUM KlinikumsMünchen, GermanyContact: Sabine KestingTaking people
- DIAKONEO Klinik Hallerwiese-Cnopfsche Kinderklinik Nürnberg, Department of Pediatric Hematology and OncologyNuremberg, GermanyContact: Jörg LeyhTaking people
- Klinikum der Landeshauptstadt Stuttgart, Zentrum für Kinder-, Jugend- und Frauenmedizin, PädiatrieStuttgart, GermanyContact: Claudia BlattmannTaking people
- University Medical Center Ulm, Department of Pediatrics and Adolescent MedicineUlm, GermanyContact: Miriam ErlacherTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Universität Duisburg-Essen
- Trial code
- NCT07647471
- Record updated
- 11 September 2026
- Original description
The BEPPO study is a Germany-wide clinical trial investigating whether a structured exercise program can improve physical and mental health in children and adolescents undergoing cancer treatment. Although exercise is known to support recovery and well-being, it is not yet a standard part of pediatric oncology care. The study aims to generate evidence to support the integration of exercise into routine treatment.Read full original descriptionShow less
Evaluation of an Exercise Intervention During Intensive Medical Treatment in Pediatric Oncology (Evaluation BEwegungs- Und sPorttherapeutischer Interventionen Unter Medizinischer Therapie in Der Pädiatrischen Onkologie)
The BEPPO study is a Germany-wide clinical trial investigating whether a structured exercise program can improve physical and mental health in children and adolescents undergoing cancer treatment. Although exercise is known to support recovery and well-being, it is not yet a standard part of pediatric oncology care. The study aims to generate evidence to support the integration of exercise into routine treatment.
A total of 346 patients aged 3 to 18 years are recruited across 13 pediatric oncology centers in Germany. Participants are randomly assigned to either an exercise intervention group or a standard care control group.
Children in the intervention group take part in a 6-month individualized exercise program with 3-5 sessions per week. The program is delivered across different settings, including inpatient hospital care, outpatient treatment, and home-based training supported by telemedicine. This ensures continuous support throughout the course of medical treatment.
In addition to supervised exercise sessions, participants receive four structured counseling sessions. These sessions aim to strengthen motivation, address individual barriers to participation, and support long-term engagement in physical activity. The counseling also helps build a strong therapeutic relationship and promotes adherence to the program.
The exercise intervention is based on established principles of sports science but is individually adapted to each patient's health status, treatment phase, and personal preferences. Each training session follows a structured plan with specific goals, while also considering individual physical and psychological conditions to ensure safety, feasibility, and effectiveness.
The main objective of the BEPPO study is to improve physical performance, particularly leg strength, which is the primary endpoint. Secondary outcomes include endurance, functional mobility, balance, physical activity levels, fatigue, quality of life, mental well-being, frailty, and treatment-related symptoms and side effects.
In addition to clinical effectiveness, the study also evaluates how well the intervention can be implemented in routine healthcare settings. This includes assessing adherence, feasibility, and potential barriers and facilitators for integrating exercise into standard care. A health economic evaluation is also conducted in collaboration with health insurance providers to determine cost implications.
Overall, the BEPPO study aims to provide robust scientific evidence on the benefits and feasibility of structured exercise during pediatric cancer treatment. The long-term goal is to establish exercise as a standard component of supportive care in pediatric oncology, improving both short- and long-term outcomes for patients.
Inclusion: Patients aged ≥3 and ≤18 years; Oncological diagnosis with curative treatment intent; ≤6 weeks since cancer diagnosis (diagnosis can be initial, secondary or relapse diagnosis); Information and consent procedures feasible in German, English or with using local site resources (e.g., interpreters or multilingual staff); Communication with the patient is possible in German, English or with using local site resources (e.g., interpreters or multilingual staff) during the assessments and intervention; Patients insured by German statutory health insurers.
Exclusion: No active medical oncological treatment (e.g., watch-and-wait strategy, surgery without ongoing oncological acute treatment at a pediatric oncology center); Patients aged <3 and >18 years; Medical limitations that do not allow implementation of the study protocol; Life expectancy < 6 months; Patients not insured by German statutory health insurers (e.g., Privatly insured patients, self-paying patients).